BACKGROUND: Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative inflammatory disorder commonly associated with human immunodeficiency virus (HIV). Its presentation may be difficult to distinguish from HIV and its complications, including lymphoma. Novel imaging strategies could address these problems. METHODS: We prospectively characterized (18)F-fluorodeoxyglucose positron emission tomography (PET) findings in 27 patients with KSHV-MCD. Patients were imaged with disease activity and at remission with scans evaluated blind to clinical status. Symptoms, C-reactive protein level, and HIV and KSHV loads were assessed in relation to imaging findings. RESULTS: KSHV-MCD activity was associated with hypermetabolic symmetric lymphadenopathy (median maximal standardized uptake value [SUVmax], 6.0; range, 2.0-8.0) and splenomegaly (3.4; 1.2-11.0), with increased metabolism also noted in the marrow (2.1; range, 1.0-3.5) and salivary glands (3.0; range, 2.0-6.0). The (18)F-fluorodeoxyglucose PET abnormalities improved at remission, with significant SUVmax decreases in the lymph nodes (P = .004), spleen (P = .008), marrow (P = .004), and salivary glands (P = .004). Nodal SUVmax correlated with symptom severity (P = .005), C-reactive protein level (R = 0.62; P = .004), and KSHV load (R = 0.54; P = .02) but not HIV load (P = .52). CONCLUSIONS: KSHV-MCD activity is associated with (18)F-FDG PET abnormalities of the lymph nodes, spleen, marrow, and salivary glands. These findings have clinical implications for the diagnosis and monitoring of KSHV-MCD and shed light on its pathobiologic mechanism. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative inflammatory disorder commonly associated with human immunodeficiency virus (HIV). Its presentation may be difficult to distinguish from HIV and its complications, including lymphoma. Novel imaging strategies could address these problems. METHODS: We prospectively characterized (18)F-fluorodeoxyglucose positron emission tomography (PET) findings in 27 patients with KSHV-MCD. Patients were imaged with disease activity and at remission with scans evaluated blind to clinical status. Symptoms, C-reactive protein level, and HIV and KSHV loads were assessed in relation to imaging findings. RESULTS:KSHV-MCD activity was associated with hypermetabolic symmetric lymphadenopathy (median maximal standardized uptake value [SUVmax], 6.0; range, 2.0-8.0) and splenomegaly (3.4; 1.2-11.0), with increased metabolism also noted in the marrow (2.1; range, 1.0-3.5) and salivary glands (3.0; range, 2.0-6.0). The (18)F-fluorodeoxyglucose PET abnormalities improved at remission, with significant SUVmax decreases in the lymph nodes (P = .004), spleen (P = .008), marrow (P = .004), and salivary glands (P = .004). Nodal SUVmax correlated with symptom severity (P = .005), C-reactive protein level (R = 0.62; P = .004), and KSHV load (R = 0.54; P = .02) but not HIV load (P = .52). CONCLUSIONS:KSHV-MCD activity is associated with (18)F-FDG PET abnormalities of the lymph nodes, spleen, marrow, and salivary glands. These findings have clinical implications for the diagnosis and monitoring of KSHV-MCD and shed light on its pathobiologic mechanism. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Mark N Polizzotto; Thomas S Uldrick; Victoria Wang; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Stefania Pittaluga; Deirdre O'Mahony; Denise Whitby; Giovanna Tosato; Seth M Steinberg; Richard F Little; Robert Yarchoan Journal: Blood Date: 2013-10-30 Impact factor: 22.113
Authors: T Mochizuki; E Tsukamoto; Y Kuge; K Kanegae; S Zhao; K Hikosaka; M Hosokawa; M Kohanawa; N Tamaki Journal: J Nucl Med Date: 2001-10 Impact factor: 10.057
Authors: Alexander M Scharko; Scott B Perlman; Robert W Pyzalski; Franklin M Graziano; James Sosman; C David Pauza Journal: Lancet Date: 2003-09-20 Impact factor: 79.321
Authors: J C Hillier; P Shaw; R F Miller; J D Cartledge; M Nelson; M Bower; N Francis; S P Padley Journal: Clin Radiol Date: 2004-07 Impact factor: 2.350
Authors: Jana M Kainerstorfer; Mark N Polizzotto; Thomas S Uldrick; Rafa Rahman; Moinuddin Hassan; Laleh Najafizadeh; Yasaman Ardeshirpour; Kathleen M Wyvill; Karen Aleman; Paul D Smith; Robert Yarchoan; Amir H Gandjbakhche Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240
Authors: Emilio Letang; James J Lewis; Mark Bower; Anisa Mosam; Margareth Borok; Thomas B Campbell; Denise Naniche; Tom Newsom-Davis; Fahmida Shaik; Suzanne Fiorillo; Jose M Miro; David Schellenberg; Philippa J Easterbrook Journal: AIDS Date: 2013-06-19 Impact factor: 4.177
Authors: David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim Journal: Blood Date: 2017-01-13 Impact factor: 22.113
Authors: Antonino Carbone; Margaret Borok; Blossom Damania; Annunziata Gloghini; Mark N Polizzotto; Raj K Jayanthan; David C Fajgenbaum; Mark Bower Journal: Nat Rev Dis Primers Date: 2021-11-25 Impact factor: 65.038
Authors: Mark N Polizzotto; Thomas S Uldrick; Kathleen M Wyvill; Karen Aleman; Vickie Marshall; Victoria Wang; Denise Whitby; Stefania Pittaluga; Elaine S Jaffe; Corina Millo; Giovanna Tosato; Richard F Little; Seth M Steinberg; Irini Sereti; Robert Yarchoan Journal: Clin Infect Dis Date: 2015-12-12 Impact factor: 9.079